StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Jointown Pharmaceutical Group Co., Ltd. logo

Jointown Pharmaceutical Group Co., Ltd.

600998 · XSHG · Medical Distribution · China

Market Capitalization26.57B CNY
Trailing P/E9.58 CNY
52-Week Change2.29 CNY
Forward Annual Dividend Yield3.75%
Beta0.3260 CNY

Jointown Pharmaceutical Group Co., Ltd. is a comprehensive pharmaceutical company based in China. It primarily engages in the distribution and wholesale of pharmaceutical products, including active pharmaceutical ingredients, biological drugs, and traditional Chinese medicine. The company's core function is to bridge the gap between pharmaceutical manufacturers and end-users, such as hospitals, clinics, and retail pharmacies. Jointown stands out in the industry by leveraging advanced logistics and distribution networks that ensure the timely delivery of healthcare products across various regions. Its operations are crucial in the healthcare supply chain, impacting both urban and rural healthcare facilities by enhancing access to essential medicines. As one of the largest pharmaceutical distribution firms in China, Jointown plays a pivotal role in ensuring the efficiency and reliability of drug delivery systems. Reflecting the rapid growth and development in China's healthcare sector, the company contributes significantly to public health by facilitating widespread distribution and availability of quality pharmaceuticals.

Industry

Medical Distribution

Healthcare sector · China

Stories

Structural patterns identified in Jointown Pharmaceutical Group Co., Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
26.57BCNY
NormalMar 19, 2026
Trailing P/E
9.58CNY
NormalMar 19, 2026
Revenue (TTM)
157.71BCNY
NormalMar 19, 2026
Profit Margin
1.77%
NormalMar 19, 2026
Beta
0.3260CNY
NormalMar 19, 2026
52-Week Change
2.29CNY
ExtremeMar 19, 2026
Forward Annual Dividend Yield
3.75%
NormalMar 19, 2026
Forward Yield
3.75%
Annual Rate
CNY 0.20
Paid unknown
Payout Ratio
36.4%
Sustainable
Loading dividend history...

Track Record

Frequency
Unknown
Payback Period
26.9 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Jun 17, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
26.57BCNY
NormalMar 19, 2026
Enterprise Value
34.26BCNY
NormalMar 19, 2026
Trailing P/E
9.58CNY
NormalMar 19, 2026
Forward P/E
10.63CNY
NormalMar 19, 2026
PEG Ratio
10.63CNY
ExtremeMar 19, 2026
Price to Sales (TTM)
0.1685CNY
NormalMar 19, 2026
Price to Book (MRQ)
1.04CNY
NormalMar 19, 2026
Enterprise to Revenue
0.2170CNY
NormalMar 19, 2026
Enterprise to EBITDA
8.12CNY
NormalMar 19, 2026
Profitability & Growth59
Gross Margin
7.81%
NormalMar 19, 2026
Profit Margin
1.77%
NormalMar 19, 2026
Operating Margin
2.74%
NormalMar 19, 2026
Return on Assets (TTM)
0.0206CNY
NormalMar 19, 2026
Return on Equity (TTM)
0.0911CNY
NormalMar 19, 2026
Revenue (TTM)
157.71BCNY
NormalMar 19, 2026
Revenue per Share (TTM)
31.09CNY
NormalMar 19, 2026
Quarterly Revenue Growth
0.0540CNY
NormalMar 19, 2026
Gross Profit (TTM)
11.96BCNY
NormalMar 19, 2026
EBITDA
6.21BCNY
ExtremeMar 19, 2026
Net Income (TTM)
2.79BCNY
NormalMar 19, 2026
Quarterly Earnings Growth (YoY)
0.0850CNY
NormalMar 19, 2026
Operating Cash Flow (TTM)
3.42BCNY
NormalMar 19, 2026
Levered Free Cash Flow (TTM)
687.06MCNY
NormalMar 19, 2026
Forward Annual Dividend Rate
0.2000CNY
NormalMar 19, 2026
Forward Annual Dividend Yield
3.75%
NormalMar 19, 2026
Trailing Annual Dividend Rate
0.2000CNY
NormalMar 19, 2026
Trailing Annual Dividend Yield
3.75%
NormalMar 19, 2026
Payout Ratio
0.3636CNY
NormalMar 19, 2026
Minority Interest (Equity)
6.35B
NormalFY2024 · Dec 31, 2024
Revenue
151.81B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
139.97B
NormalFY2024 · Dec 31, 2024
Gross Profit
11.84B
NormalFY2024 · Dec 31, 2024
Operating Income
4.21B
NormalFY2024 · Dec 31, 2024
Pre-tax Income
3.64B
NormalFY2024 · Dec 31, 2024
Income Tax Expense
851.03M
NormalFY2024 · Dec 31, 2024
Net Income
2.79B
NormalFY2024 · Dec 31, 2024
EBIT
4.92B
NormalFY2024 · Dec 31, 2024
ebitda-income
6.48B
NormalFY2024 · Dec 31, 2024
Research & Development
146.70M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
3.21B
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
470.19M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
171.05M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
1.28B
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.5000
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.5000
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
5.01BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
5.01BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
2.79B
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
-279.05M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
-3.96B
NormalFY2024 · Dec 31, 2024
Free Cash Flow
2.11B
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
7.80B
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
2.79B
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
779.34M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-4.62B
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
-2.91B
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-952.60M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
712.47M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-907.38M
NormalFY2024 · Dec 31, 2024
Sale of Investments
296.45M
NormalFY2024 · Dec 31, 2024
Other Investing Activity
-740.68M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-1.59B
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
17.04B
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-18.60B
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-1.55B
NormalFY2024 · Dec 31, 2024
Other Financing Charges
879.82M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-2.24B
NormalFY2024 · Dec 31, 2024
Financial Strength31
Shares Outstanding
5.04BShares
NormalMar 19, 2026
Float Shares
2.22BCNY
NormalMar 19, 2026
% Held by Insiders
0.5642CNY
NormalMar 19, 2026
% Held by Institutions
0.1265CNY
NormalMar 19, 2026
Total Cash (MRQ)
18.15BCNY
NormalMar 19, 2026
Total Cash per Share (MRQ)
3.47CNY
NormalMar 19, 2026
Total Debt (MRQ)
15.97BCNY
NormalMar 19, 2026
Total Debt to Equity (MRQ)
45.53CNY
ExtremeMar 19, 2026
Current Ratio (MRQ)
1.25CNY
NormalMar 19, 2026
Book Value per Share (MRQ)
5.07CNY
NormalMar 19, 2026
Total Assets
102.40B
NormalFY2024 · Dec 31, 2024
Total Current Assets
84.22B
NormalFY2024 · Dec 31, 2024
Total Liabilities
68.80B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
18.17B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
2.40B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
66.40B
NormalFY2024 · Dec 31, 2024
Cash
7.71B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
9.68B
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
17.39B
NormalFY2024 · Dec 31, 2024
Other Short-term Investments
972.34M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
29.48B
NormalFY2024 · Dec 31, 2024
Inventory
22.85B
NormalFY2024 · Dec 31, 2024
Accounts Payable
46.51B
NormalFY2024 · Dec 31, 2024
Short-term Debt
11.51B
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
179.61M
NormalFY2024 · Dec 31, 2024
Long-term Debt
1.72B
NormalFY2024 · Dec 31, 2024
Other Non-current Liabilities
102.73M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
5.04B
NormalFY2024 · Dec 31, 2024
Retained Earnings
14.07B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
33.59B
NormalFY2024 · Dec 31, 2024
Treasury Stock
632.46M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
4.57CNY
NormalMar 19, 2026
52-Week High
5.84CNY
NormalMar 19, 2026
52-Week Change
2.29CNY
ExtremeMar 19, 2026
Beta
0.3260CNY
NormalMar 19, 2026
50-Day MA
5.28CNY
NormalMar 19, 2026
200-Day MA
5.17CNY
NormalMar 19, 2026
Avg 10-Day Volume
32.18MCNY
NormalMar 19, 2026
Avg 30-Day Volume
39.20MCNY
NormalMar 19, 2026
Diluted EPS (TTM)
0.5500CNY
NormalMar 19, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Blood Supply Chain

The blood supply chain is shaped by three root constraints: biological perishability that gives red blood cells a 42-day shelf life and platelets just 5 days — making stockpiling impossible, voluntary donor dependency that means the raw material cannot be manufactured and fluctuates with seasons and public events, and a type-matching requirement that forces individual testing of every unit — creating a processing bottleneck between collection and availability.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.